BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 9802348)

  • 1. Cyclin D1 and MIB-1 immunohistochemistry in ependymomas: a study of 41 cases.
    Prayson RA
    Am J Clin Pathol; 1998 Nov; 110(5):629-34. PubMed ID: 9802348
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinicopathologic study of 61 patients with ependymoma including MIB-1 immunohistochemistry.
    Prayson RA
    Ann Diagn Pathol; 1999 Feb; 3(1):11-8. PubMed ID: 9990108
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyclin D1 and MIB-1 immunohistochemistry in pilocytic astrocytomas: a study of 48 cases.
    Machen SK; Prayson RA
    Hum Pathol; 1998 Dec; 29(12):1511-6. PubMed ID: 9865840
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ependymomas: MIB-1 proliferation index and survival.
    Ritter AM; Hess KR; McLendon RE; Langford LA
    J Neurooncol; 1998 Oct; 40(1):51-7. PubMed ID: 9874186
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Apoptotic and proliferative markers in chordomas: a study of 26 tumors.
    Kilgore S; Prayson RA
    Ann Diagn Pathol; 2002 Aug; 6(4):222-8. PubMed ID: 12170453
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Subependymomas: clinicopathologic study of 14 tumors, including comparative MIB-1 immunohistochemical analysis with other ependymal neoplasms.
    Prayson RA; Suh JH
    Arch Pathol Lab Med; 1999 Apr; 123(4):306-9. PubMed ID: 10320142
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunohistochemical expression of cyclin D1 is higher in supratentorial ependymomas and predicts relapses in gross total resection cases.
    de Andrade FG; Marie SK; Uno M; Matushita H; Taricco MA; Teixeira MJ; Rosemberg S; Oba-Shinjo SM
    Neuropathology; 2015 Aug; 35(4):312-23. PubMed ID: 25946121
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical significance of the histological and molecular characteristics of ependymal tumors: a single institution case series from China.
    Xi S; Sai K; Hu W; Wang F; Chen Y; Wang J; Zeng J; Chen Z
    BMC Cancer; 2019 Jul; 19(1):717. PubMed ID: 31324163
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Myxopapillary ependymomas: a clinicopathologic study of 14 cases including MIB-1 and p53 immunoreactivity.
    Prayson RA
    Mod Pathol; 1997 Apr; 10(4):304-10. PubMed ID: 9110291
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation of bcl-2, p53, and MIB-1 expression with ependymoma grade and subtype.
    Rushing EJ; Brown DF; Hladik CL; Risser RC; Mickey BE; White CL
    Mod Pathol; 1998 May; 11(5):464-70. PubMed ID: 9619600
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pediatric intracranial ependymomas: prognostic relevance of histological, immunohistochemical, and flow cytometric factors.
    Zamecnik J; Snuderl M; Eckschlager T; Chanova M; Hladikova M; Tichy M; Kodet R
    Mod Pathol; 2003 Oct; 16(10):980-91. PubMed ID: 14559980
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of Ki-67 (MIB-1) and p53 in ependymomas.
    Suzuki S; Oka H; Kawano N; Tanaka S; Utsuki S; Fujii K
    Brain Tumor Pathol; 2001; 18(2):151-4. PubMed ID: 11908872
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Central neurocytoma: histologic atypia, proliferation potential, and clinical outcome.
    Mackenzie IR
    Cancer; 1999 Apr; 85(7):1606-10. PubMed ID: 10193953
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of telomerase RNA component correlates with the MIB-1 proliferation index in ependymomas.
    Rushing EJ; Yashima K; Brown DF; White CL; Shay JW; Risser RC; Gazdar AF
    J Neuropathol Exp Neurol; 1997 Oct; 56(10):1142-6. PubMed ID: 9329458
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A clinicopathologic study of 81 patients with ependymomas and proposal of diagnostic criteria for anaplastic ependymoma.
    Ho DM; Hsu CY; Wong TT; Chiang H
    J Neurooncol; 2001 Aug; 54(1):77-85. PubMed ID: 11763426
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A case of cervicomedullary junction tanycytic ependymoma associated with marked cyst formation.
    Ito T; Ozaki Y; Nakagawara J; Nakamura H; Tanaka S; Nagashima K
    Brain Tumor Pathol; 2005; 22(1):29-33. PubMed ID: 18095101
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Therapeutic results of eight patients with intracranial ependymomas].
    Sasajima T; Takahashi M; Kinouchi H; Suzuki A; Mizoi K
    No To Shinkei; 2003 Mar; 55(3):233-40. PubMed ID: 12728504
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The proliferative potential of the pilocytic astrocytoma: the relation between MIB-1 labeling and clinical and neuro-radiological follow-up.
    Dirven CM; Koudstaal J; Mooij JJ; Molenaar WM
    J Neurooncol; 1998 Mar; 37(1):9-16. PubMed ID: 9525833
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic marker analysis in pediatric intracranial ependymomas.
    McLendon RE; Lipp E; Satterfield D; Ehinger M; Austin A; Fleming D; Perkinson K; Lefaivre M; Zagzag D; Wiener B; Gururangan S; Fuchs H; Friedman HS; Herndon JE; Healy P
    J Neurooncol; 2015 Apr; 122(2):255-61. PubMed ID: 25563815
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of relevant prognostic histopathologic features in 69 intracranial ependymomas, excluding myxopapillary ependymomas and subependymomas.
    Kurt E; Zheng PP; Hop WC; van der Weiden M; Bol M; van den Bent MJ; Avezaat CJ; Kros JM
    Cancer; 2006 Jan; 106(2):388-95. PubMed ID: 16342252
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.